Press release
Investigation for Investors in NASDAQ: ARDX shares over possible Wrongdoing at Ardelyx, Inc. announced
An investigation on behalf of investors in Ardelyx, Inc. (NASDAQ: ARDX) shares over potential wrongdoing at Ardelyx, Inc.
Investors who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Ardelyx, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
An investor in shares of Ardelyx, Inc. (NASDAQ: ARDX) filed a lawsuit against certain directors of Ardelyx, Inc over alleged breaches of fiduciary duties. The plaintiff alleges that certain directors engaged in insider trading and made false and misleading statements about Ardelyx's lead product candidate, tenapanor that lead to a 74% stock drop after regulators found issues with certain data about the drug. The lawsuit against certain directors over alleged breaches of fiduciary duties follows a lawsuit that was filed against Ardelyx over alleged Securities Laws Violations. According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that Ardelyx and the other named defendants made materially false and misleading statements regarding tenapanor and the likelihood that it would be approved by the FDA, which led investors to suffer significant losses.
Those who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in NASDAQ: ARDX shares over possible Wrongdoing at Ardelyx, Inc. announced here
News-ID: 2718170 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Ardelyx
Short Bowel Syndrome Market Deep Research 2025-2032 | Ardelyx, Inc., Emmaus Life …
The Global Short Bowel Syndrome Market is expected to grow at CAGR 21.6% from 2025 to 2032.
The Latest comprehensive Research Report on the Short Bowel Syndrome Market 2025-2032, Outlook is performed by determining industry drivers, dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. The Short Bowel Syndrome Market report has…
Hyperkalemia Treatment Market Moving in the Right Direction: AstraZeneca, Ardely …
The latest study released on the Global Hyperkalemia Treatment Market by HTF MI Research evaluates market size, trend, and forecast to 2030. The Hyperkalemia Treatment market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
Hyperphosphatemia Market to Witness Upsurge in Growth During the Forecast Period …
DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast
https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Hyperphosphatemia…
Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit filed against Di …
An investor in shares of Ardelyx, Inc. (NASDAQ: ARDX) filed a lawsuit against certain directors of Ardelyx, Inc over alleged breaches of fiduciary duties.
Investors who are current long term investors in Ardelyx, Inc. (NASDAQ: ARDX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff alleges that certain directors engaged in insider trading and made false and misleading statements about…
Lawsuit filed for Investors in shares of Ardelyx, Inc. (NASDAQ: ARDX)
An investor, who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX), filed a lawsuit over alleged violations of Federal Securities Laws by Ardelyx, Inc.
Investors who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 28, 2021. NASDAQ: ARDX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Fremont, CA based Ardelyx, Inc., a biopharmaceutical…
Investigation announced for Investors in Ardelyx, Inc. (NASDAQ: ARDX) shares
An investigation was announced concerning potential securities laws violations by Ardelyx, Inc. in connection with certain financial statements.
Investors who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Ardelyx, Inc. regarding its business, its prospects and its operations were materially false and…
